OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.

OnKure Therapeutics, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on McKesson (MCK) and OnKure Therapeutics (OKUR) with b...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OKUR	$3.79	-1.04%	432.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OKUR	$3.79	-1.0%	432.47K
3
4
5
6

OKUR

Get OnKure Therapeutics, Inc. Data in Excel

Get OnKure Therapeutics, Inc. Data in Excel